Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note issued to investors on Monday. HC Wainwright currently has a $2.00 price target on the biopharmaceutical company’s stock.
A number of other analysts have also recently commented on the stock. Jefferies Financial Group reiterated a hold rating on shares of Celldex Therapeutics in a research note on Friday, August 10th. Cowen reiterated a hold rating on shares of Celldex Therapeutics in a research note on Thursday, August 9th. Finally, Zacks Investment Research cut shares of Celldex Therapeutics from a hold rating to a sell rating in a research note on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. Celldex Therapeutics currently has an average rating of Hold and a consensus target price of $3.75.
CLDX stock opened at $0.33 on Monday. Celldex Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.09.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Featured Story: Ex-Dividend
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.